Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes
Status:
Active, not recruiting
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of
combination zonisamide and bupropion on the process of switching from combustible cigarettes
(CC) to an e-cigarette. There will be a data collection period of at least five days to
obtain baseline data on use of combustible cigarettes. Participants enrolled in the study
will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette
use, (at V3) participants will be given zonisamide (100 mg/daily) and will begin
extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) in
addition to continued use of the G6. At each visit, participants will receive enough
zonisamide, bupropion, and Halo G6 cartomizers to last until their next study visit. Halo G6
and combination zonisamide and bupropion use will continue until the participant returns for
the End-of-Study visit (V7).